CID 2745687|cas:264233-05-8|西域试剂

CID 2745687,98.07%

产品编号：Bellancom-107537| CAS NO：264233-05-8| 分子式：C₁₇H₁₉F₂N₅O₂S| 分子量：395.43

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-107537	￥1300.00	杭州北京（现货）
Bellancom-107537	￥2080.00	杭州北京（现货）
Bellancom-107537	￥4550.00	杭州北京（现货）
Bellancom-107537	￥7150.00	杭州北京（现货）
Bellancom-107537	￥12350.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

CID 2745687

产品介绍

CID 2745687 是一种特异性、可逆和竞争性的 GPR35 拮抗剂，K_i 为 12.8 nM。

生物活性

CID 2745687 acts as a specific, reversible and competitive GPR35 antagonist with a K_i of 12.8 nM.

体外研究

For ERK1/2 phosphorylation with 1 μM Pamoic acid as the agonist, the CID 2745687 (CID2745687) K_i is 18 nM. CID 2745687 (CID-2745687) is a potent antagonist in β-arrestin-2 interaction assays only at human GPR35.
Using the BRET-based GPR35-β-arrestin-2 interaction assay and an EC₈₀ concentration of Zaprinast (20 μM) as agonist, CID 2745687 behaved as a moderately potent, concentration-dependent antagonist at human GPR35 with pIC₅₀=6.70±0.09.
CID 2745687 (pIC₅₀=6.27±0.08) fully reverses the agonist action of Cromolyn disodium .

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

CID 2745687 (CID2745687; 1 mg/kg; administrated orally every day for the last 4 weeks), a specific GPR35 antagonist, reverses Lodoxamide-mediated anti-fibrotic effects.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Six-week-old male C57BL/6 mice
Dosage:	1 mg/kg
Administration:	Oral administration, every day for 4 weeks
Result:	Inhibited Lodoxamide-mediated protective effects.

体内研究

CID 2745687 (CID2745687; 1 mg/kg; administrated orally every day for the last 4 weeks), a specific GPR35 antagonist, reverses Lodoxamide-mediated anti-fibrotic effects.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Six-week-old male C57BL/6 mice
Dosage:	1 mg/kg
Administration:	Oral administration, every day for 4 weeks
Result:	Inhibited Lodoxamide-mediated protective effects.

性状

Solid

溶解性数据

In Vitro:

DMSO : 125 mg/mL (316.11 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.5289 mL	12.6445 mL	25.2889 mL
5 mM	0.5058 mL	2.5289 mL	5.0578 mL
10 mM	0.2529 mL	1.2644 mL	2.5289 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.26 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.26 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。